NKTX (Nkarta, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by NKTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | PAUL J HASTINGS | Chief Executive Officer | Sell | — | — |
| 2026-06-11 | George Vratsanos | Director | A | — | — |
| 2026-06-11 | LEONE D PATTERSON | Director | A | — | — |
| 2026-06-11 | Michael Dybbs | Director | A | — | — |
| 2026-06-11 | Zachary Scheiner | Director | A | — | — |
| 2026-06-11 | Ali Behbahani | Director | A | — | — |
| 2026-06-11 | Simeon George | Director | A | — | — |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | Director | A | — | — |
| 2026-06-11 | Angela Thedinga | Director | A | — | — |
| 2026-01-20 | Nadir Mahmood | President | Sell | — | — |
| 2026-01-20 | PAUL J HASTINGS | Chief Executive Officer | Sell | — | — |
| 2026-01-08 | Shawn Marshall Rose | See Remarks | A | — | — |
| 2026-01-08 | Nadir Mahmood | President | A | — | — |
| 2026-01-08 | PAUL J HASTINGS | Chief Executive Officer | A | — | — |
| 2025-06-25 | Shawn Marshall Rose | See Remarks | A | — | — |
| 2025-06-20 | PAUL J HASTINGS | Chief Executive Officer | Sell | — | — |
| 2025-06-09 | George Vratsanos | Director | A | — | — |
| 2025-06-09 | Simeon George | Director | A | — | — |
| 2025-06-09 | Ali Behbahani | Director | A | — | — |
| 2025-06-09 | Zachary Scheiner | Director | A | — | — |
| 2025-06-09 | LEONE D PATTERSON | Director | A | — | — |
| 2025-06-09 | Angela Thedinga | Director | A | — | — |
| 2025-06-09 | Michael Dybbs | Director | A | — | — |
| 2025-06-09 | PAUL J HASTINGS | Chief Executive Officer | A | — | — |
| 2025-06-09 | Nadir Mahmood | President | A | — | — |
| 2025-06-09 | Rajeev M. Shah | Director | A | — | — |
| 2025-01-17 | David Shook | See Remarks | Sell | — | — |
| 2025-01-17 | PAUL J HASTINGS | Chief Executive Officer | Sell | — | — |
| 2025-01-17 | Ralph Brandenberger | Chief Technical Officer | Sell | — | — |
| 2025-01-17 | Alyssa Levin | See Remarks | Sell | — | — |
| 2025-01-17 | Alicia J. Hager | Chief Legal Officer | Sell | — | — |
| 2025-01-07 | David Shook | See Remarks | A | — | — |
| 2025-01-07 | Ralph Brandenberger | Chief Technical Officer | A | — | — |
| 2025-01-07 | Alyssa Levin | See Remarks | A | — | — |
| 2025-01-07 | PAUL J HASTINGS | Chief Executive Officer | A | — | — |
| 2025-01-07 | Nadir Mahmood | President | A | — | — |
| 2025-01-07 | Alicia J. Hager | Chief Legal Officer | A | — | — |
| 2024-08-23 | David Shook | See Remarks | A | — | — |
| 2024-07-31 | Nadir Mahmood | President | A | — | — |
| 2024-07-31 | David Shook | See Remarks | A | — | — |
| 2024-07-18 | Alicia J. Hager | Chief Legal Officer | Sell | — | — |
| 2024-06-20 | Alicia J. Hager | Chief Legal Officer | Sell | — | — |
| 2024-06-20 | PAUL J HASTINGS | Chief Executive Officer | Sell | — | — |
| 2024-06-20 | James Trager | Chief Scientific Officer | Sell | — | — |
| 2024-06-20 | David Shook | Chief Medical Officer | Sell | — | — |
| 2024-06-20 | Ralph Brandenberger | Chief Technical Officer | Sell | — | — |
| 2024-06-14 | Angela Thedinga | Director | A | — | — |
| 2024-06-14 | Zachary Scheiner | Director | A | — | — |
| 2024-06-14 | LEONE D PATTERSON | Director | A | — | — |
| 2024-06-14 | George Vratsanos | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 7,805,129 | — |
| — | 10%+ Owner | 2,902,115 | — |
| — | 10%+ Owner | 2,793,865 | — |
| — | Director | 2,271,796 | — |
| — | 10%+ Owner | 2,235,449 | — |
| — | 10%+ Owner | 2,235,449 | — |
| — | 10%+ Owner | 2,235,449 | — |
| — | Director | 754,311 | — |
| — | Director | 754,311 | — |
| — | 10%+ Owner | 709,936 | — |
| — | Director | 666,667 | — |
| — | Director | 604,589 | — |
| — | 10%+ Owner | 522,639 | — |
| — | 10%+ Owner | 522,639 | — |
| — | 10%+ Owner | 522,639 | — |
| — | Chief Executive Officer | 390,247 | — |
| — | See Remarks | 190,955 | — |
| — | President | 167,727 | — |
| — | Chief Scientific Officer | 150,959 | — |
| — | Chief Legal Officer | 146,735 | — |
| — | Chief Technical Officer | 124,796 | — |
| — | See Remarks | 102,662 | — |
| — | See Remarks | 70,000 | — |
| — | Chief Medical Officer | 12,800 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NKTX quote page; the site-wide leaderboard is on the insider transactions hub.